Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anai.2019.11.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and oncological effectiveness after desensitization in patients with previous hypersensitivity reactions to chemotherapy.
J Oncol Pharm Pract
August 2024
Oncology Service, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario "Dr José Eleuterio González", Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México.
Introduction: Taxanes and platinum are first-line treatments in gynecological tumors with high rates of hypersensitivity reactions (HSRs), leading to discontinuation of treatment. Desensitization involves induction of temporary tolerance to previously sensitized medications. The aims of this study are to describe HSRs to paclitaxel and carboplatin and evaluate the safety and effectiveness of desensitization protocols in gynecological cancer patients.
View Article and Find Full Text PDFRapid drug desensitization to taxanes: a descriptive study from Turkey.
J Oncol Pharm Pract
December 2024
Division of Immunology and Allergy, University of Health Sciences, Ankara Atatürk Sanatory Education and Research Hospital, Ankara, Turkey.
Aim: To present the characteristics of drug hypersensitivity reactions (DHRs) among taxane recipients with non-small cell lung carcinoma (NSCLC), and to describe the results of rapid drug desensitization (RDD).
Methods: A retrospective cross-sectional study included 45 patients who were treated with taxane for NSCLC and were found to be hypersensitive to taxane. All patients were administered the standard 3-bag, 12-step RDD protocol following the development of DHR.
Hypersensitivity Reactions to Taxanes: A Comprehensive and Systematic Review of the Efficacy and Safety of Desensitization.
Clin Rev Allergy Immunol
October 2023
Division of Allergy and Immunology, Department of Medicine, Brigham and Women's Hospital/Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Taxanes in the treatment of cancer are associated with a significant incidence of hypersensitivity reactions, which may preclude their use in patients in need of first line therapy. Drug desensitization induces transient immunological tolerance and has allowed the reintroduction of taxanes in highly allergic patients. Increase the knowledge of hypersensitivity reactions (HSR) during the administration of taxanes.
View Article and Find Full Text PDFHypersensitivity reactions to paclitaxel: The Mexican experience of rapid desensitization.
J Oncol Pharm Pract
April 2022
Regional Center of Allergy and Clinical Immunology, University Hospital "Dr, José Eleuterio González", Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico.
Background: Taxanes adjuvant therapy is recommended in certain high risk or metastatic tumors, particularly in lung and breast cancer, but also in other types of cancer like ovarian. The incidence of severe adverse drug reactions to paclitaxel is of approximately 10%.
Objectives: Analyze type I hypersensitivity reactions to paclitaxel and their management in the Mexican population.
Rapid desensitization to brentuximab vedotin after severe anaphylaxis in the treatment of refractory Hodgkin's lymphoma.
J Oncol Pharm Pract
March 2021
Regional Center of Allergy and Clinical Immunology, University Hospital "Dr. Jose Eleuterio Gonzalez", Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico.
Introduction: Brentuximab vedotin is a monoclonal antibody drug conjugate used for the treatment of patients with Hodgkin lymphoma. Hypersensitivity reactions to brentuximab vedotin may include cutaneous, cardiovascular, respiratory, gastrointestinal and neurological signs and symptoms.
Case Report: We present the case of a 23-year-old Mexican female with stage IV progressive classical nodular sclerosing Hodgkin lymphoma who received multiple previous chemotherapy regimens.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!